Vaccine approaches to prevent tuberculosis

Scandinavian Journal of Immunology

Volumn 64, Issue 3, 2006, Pages 243-250

  Wiker, H G ^a,b,d   Mustafa, T ^a   Malen H ^a,b   Riise, A M D ^c  

^a UNIVERSITY OF BERGEN   (Norway)

^b Department of Microbiology and Immunology ^*  (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY MBS43; ANTIBODY MBS83; ANTIGEN 85A; ANTIGEN 85B; ANTIRETROVIRUS AGENT; BACTERIAL PROTEIN; BCG VACCINE; BIOLOGICAL MARKER; DNA VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; FAS LIGAND; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; LIPOPROTEIN; MONOCLONAL ANTIBODY; PROTEIN BCL 2; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SUBUNIT VACCINE; TUBERCLE BACILLUS MYCOBACTERIAL PROTEIN OF TUBERCULOSIS 83; UNCLASSIFIED DRUG;

APOPTOSIS; BCG VACCINATION; CELLULAR IMMUNITY; DISEASE ASSOCIATION; DISEASE TRANSMISSION; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; INFECTION CONTROL; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT RESPONSE; TUBERCULOSIS; VACCINIA VIRUS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIGENS, BACTERIAL; APOPTOSIS; BACTERIAL PROTEINS; HUMANS; MACROPHAGES; MICE; MODELS, ANIMAL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 33747068792     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2006.01815.x     Document Type: Review

References (70)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-86.
2. Kaufmann SH. Introduction. Rational vaccine development against tuberculosis: 'Those who don't remember the past are condemned to repeat it'. Microbes Infect 2005;7:897-8.
3. Haile M, Kallenius G. Recent developments in tuberculosis vaccines. Curr Opin Infect Dis 2005;18:211-5.
4. Ziv E, Daley CL, Blower S. Potential public health impact of new tuberculosis vaccines. Emerg Infect Dis 2004;10:1529-35.
5. Aronson NE, Santosham M, Comstock GW et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 2004;291:2086-91.
6. Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994;271:698-702.
7. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45 [published erratum appears in Lancet 1996 Feb 3;347(8997):340].
8. Rodrigues LC, Pereira SM, Cunha SS et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005;366:1290-5.
9. Eddine AN, Kaufmann SE. Improved protection by recombinant BCG. Microbes Infect 2005;7:939-46.
10. Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, Kaufmann SH. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci U S A 1998;95:5299-304.
11. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic' S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 2000;97:13853-8.
12. Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci U S A 1996;93:934-9.
13. McShane H, Hill A. Prime-boost immunisation strategies for tuberculosis. Microbes Infect 2005;7:962-7.
14. McShane H, Pathan AA, Sander CR et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004;10:1240-4.
15. Huygen K. Plasmid DNA vaccination. Microbes Infect 2005;7:932-8.
16. Tollefsen S, Tjelle T, Schneider J et al. Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation. Vaccine 2002;20:3370-8.
17. Andersen P, Doherty TM. TB subunit vaccines-putting the pieces together. Microbes Infect 2005;7:911-21.
18. Skeiky YA, Alderson MR, Ovendale PJ et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004;172:7618-28.
19. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004;72:6148-50.
20. Dietrich J, Aagaard C, Leah R et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005;174:6332-9.
21. Kaufmann SHE. Tuberculosis: back on the immunologists' agenda. Immunity 2006;24:351-7.
22. Glatman-Freedman A, Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 1998;11:514-32.
23. Chambers MA, Gavier-Widen D, Hewinson RG. Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge. FEMS Immunol Med Microbiol 2004;41:93-100.
24. Orme IM. The use of animal models to guide rational vaccine design. Microbes Infect 2005;7:905-10.
25. Mustafa T, Phyu S, Nilsen R, Jonsson R, Bjune G. A mouse model for slowly progressive primary tuberculosis. Scand J Immunol 1999;50:127-36.
26. Phyu S, Mustafa T, Hofstad T, Nilsen R, Fosse R, Bjune G. A mouse model for latent tuberculosis. Scand J Infect Dis 1998;30:59-68.
27. Ravn P, Demissie A, Eguale T et al. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis 1999;179:637-45.
28. Wiker HG, Harboe M, Lea TE. Purification and characterization of two protein antigens from the heterogeneous BCG85 complex in Mycobacterium bovis BCG. Int Arch Allergy Appl Immunol 1986;81:298-306.
29. Wiker HG, Harboe M, Nagai S, Patarroyo ME, Ramirez C, Cruz N. MPB59 a widely cross-reacting protein of Mycobacterium bovis BCG. Int Arch Allergy Appl Immunol 1986;81:307-14.
30. Wiker HG, Harboe M. The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 1992;56:648-61.
31. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-44 [published erratum appears in Nature 1998 Nov 12;396(6707):190].
32. Jungblut PR, Schaible UE, Mollenkopf HJ et al. Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens. Mol Microbiol 1999;33:1103-17.
33. Rosenkrands I, Weldingh K, Jacobsen S et al. Mapping and identification of Mycobacterium tuberculosis proteins by two-dimensional gel electrophoresis, microsequencing and immunodetection. Electrophoresis 2000;21:935-48.
34. Saleh MT, Fillon M, Brennan PJ, Belisle JT. Identification of putative exported/secreted proteins in prokaryotic proteomes. Gene 2001;269:195-204.
35. Sonnenberg MG, Belisle JT. Definition of Mycobacterium tuberculosis culture filtrate proteins by two-dimensional polyacrylamide gel electrophoresis, N-terminal amino acid sequencing, and electrospray mass spectrometry. Infect Immun 1997;65:4515-24.
36. Gomez M, Johnson S, Gennaro ML. Identification of secreted proteins of Mycobacterium tuberculosis by a bioinformatic approach. Infect Immun 2000;68:2323-7.
37. Wiker HG, Harboe M, Nagai S. A localization index for distinction between extracellular and intracellular antigens of mycobacterium-tuberculosis. J Gen Microbiol 1991;137:875-84.
38. Wiker HG, Målen H, Berven F, Fladmark K. Late Breaker: Revealing the Secreted Proteome of Mycobacterium tuberculosis H37Rv. 19-4-2006. Vienna, Austria, TB vaccines for the world, TBV2006.
39. Oftung F, Wiker HG, Deggerdal A, Mustafa AS. A novel mycobacterial antigen relevant to cellular immunity belongs to a family of secreted lipoproteins. Scand J Immunol 1997;46:445-51.
40. Young DB, Garbe TR. Lipoprotein antigens of mycobacterium tuberculosis. Res Microbiol 1991;142:55-65.
41. Abou-Zeid C, Gares MP, Inwald J et al. Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Infect Immun 1997;65:1856-62.
42. Hovav AH, Mullerad J, Davidovitch L et al. The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection. Infect Immun 2003;71:3146-54.
43. Glatman-Freedman A. Advances in antibody-mediated immunity against Mycobacterium tuberculosis: implications for a novel vaccine strategy. FEMS Immunol Med Microbiol 2003;39:9-16.
44. Glatman-Freedman A, Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 1998;11:514-32.
45. Harboe M, Nagai S, Wiker HG, Sletten K, Haga S. Homology between the MPB70 and MPB83 proteins of Mycobacterium bovis BCG. Scand J Immunol 1995;42:46-51.
46. Hewinson RG, Michell SL, Russell WP, McAdam RA, Jacobs WR Jr. Molecular characterization of MPT83: a seroreactive antigen of Mycobacterium tuberculosis with homology to MPT70. Scand J Immunol 1996;43:490-9.
47. Herrmann JL, O'Gaora P, Gallagher A, Thole JE, Young DB. Bacterial glycoproteins: a link between glycosylation and proteolytic cleavage of a 19 kDa antigen from Mycobacterium tuberculosis. EMBO J 1996;15:3547-54.
48. Harboe M, Wiker HG, Ulvund G et al. MPB70 and MPB83 as indicators of protein localization in mycobacterial cells. Infect Immun 1998;66:289-96.
49. Ulstrup JC, Jeansson S, Wiker HG, Harboe M. Relationship of Secretion Pattern and MPB70 Homology with Osteoblast-Specific Factor-2 to Osteitis Following Mycobacterium bovis BCG Vaccination. Infect Immun 1995;63:672-5.
50. Sander P, Rezwan M, Walker B et al. Lipoprotein processing is required for virulence of Mycobacterium tuberculosis. Mol Microbiol 2004;52:1543-52.
51. da Fonseca DP, Joosten D, van der Zee R et al. Identification of new cytotoxic T-cell epitopes on the 38-kilodalton lipoglycoprotein of Mycobacterium tuberculosis by using lipopeptides. Infect Immun 1998;66:3190-7.
52. Brightbill HD, Libraty DH, Krutzik SR et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999;285:732-6.
53. Doherty TM, Arditi M. TB, or not TB: that is the question - does TLR signaling hold the answer? J Clin Invest 2004;114:1699-703.
54. Geijtenbeek TB, Kwon DS, Torensma R et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000;100:587-97.
55. Das G, Vohra H, Saha B, Agrewala JN, Mishra GC. Apoptosis of Th1-like cells in experimental tuberculosis (TB). Clin Exp Immunol 1999;115:324-8.
56. Hirsch CS, Toossi Z, Vanham G et al. Apoptosis and T cell hyporesponsiveness in pulmonary tuberculosis. J Infect Dis 1999;179:945-53.
57. Chan J, Kaufmann SH. Immune mechanisms of protection. In: Bloom BR, ed. Tuberculosis, Pathogenesis, Protection and Control. Washington, DC: ASM Press, 1994:389-415.
58. Molloy A, Laochumroonvorapong P, Kaplan G. Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guerin. J Exp Med 1994;180:1499-509.
59. Mogga SJ, Mustafa T, Sviland L, Nilsen R. Increased Bcl-2 and reduced Bax expression in infected macrophages in slowly progressive primary murine Mycobacterium tuberculosis infection. Scand J Immunol 2002;56:383-91.
60. Sly LM, Hingley-Wilson SM, Reiner NE, McMaster WR. Survival of Mycobacterium tuberculosis in host macrophages involves resistance to apoptosis dependent upon induction of antiapoptotic Bcl-2 family member Mcl-1. J Immunol 2003;170:430-7.
61. Mustafa T, Bjune TG, Jonsson R, Pando RH, Nilsen R. Increased expression of fas ligand in human tuberculosis and leprosy lesions: a potential novel mechanism of immune evasion in mycobacterial infection. Scand J Immunol 2001;54:630-9.
62. Mustafa T, Phyu S, Nilsen R, Bjune G, Jonsson R. Increased expression of Fas ligand on Mycobacterium tuberculosis infected macrophages: a potential novel mechanism of immune evasion by Mycobacterium tuberculosis? Inflammation 1999;23:507-21.
63. Mustafa T, Mogga SJ, Mfinanga SG, Morkve O, Sviland L. Significance of Fas and Fas ligand in tuberculous lymphadenitis. Immunology 2005;114:255-62.
64. Boise LH, Thompson CB. Hierarchical control of lymphocyte survival. Science 1996;274:67-8.
65. Fraser A, Evan G. A license to kill. Cell 1996;85:781-4.
66. Manfredi AA, Heltai S, Rovere P et al. Mycobacterium tuberculosis exploits the CD95/CD95 ligand system of gammadelta T cells to cause apoptosis. Eur J Immunol 1998;28:1798-806.
67. Zhang HG, Su X, Liu D et al. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J Immunol 1999;162:1423-30.
68. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-56.
69. Hernandez-Pando R, Jeyanathan M, Mengistu G et al. Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 2000;356:2133-8.
70. Opie EL, Aronson JD. Tubercle bacilli in latent TB lesions and in lung tissue without tuberculous lesions. Arch Path Lab Med 1927;4:1-21.